Cellebrite plans U.S. redomicile and unified investigative AI platform
Cellebrite DI Ltd. (NASDAQ:CLBT) says it is moving to redomicile under a U.S. parent (pending approvals), consolidating R&D under CTO Chris Wade, and pursuing a unified investigative AI platform; DA Davidson maintains a Buy rating and $15 target, citing a goal to boost ARR ahead of H1 2027.